• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution
rhSOD

Glenmark Pharma receives USFDA approval for Sirolimus tablets

expresspharmaOctober 21, 2020

Tag: Glenmark , Sirolimus tablets , FDA

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (US FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV.

According to IQVIA sales data for the 12 month period ending August 2020, the Rapamune Tablets, 0.5 mg, 1 mg and 2 mg market achieved annual sales of approximately $119.7 million.

Glenmark’s current portfolio consists of 165 products authorised for distribution in the US marketplace and 45 ANDA’s pending approval with the US FDA.

Previous:Zydus Cadila gets tentative USFDA nod for Tofacitinib ER tablets

Next:CordenPharma Colorado Completes Highly Potent API Lab Expansion

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Glenmark Pharma receives USFDA approval for Sirolimus tablets | Pharmasources.com

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

You may like
More>>

Bumetanide (FDA)

Bumetanide (FDA)
Prednisolone (FDA /COS)

Prednisolone (FDA /COS)
Cilostazol(FDA Approved) (Micronized)

Cilostazol(FDA Approved) (Micronized)
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project

GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project
Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals

Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals
Lincomycin HCL (FDA)

Lincomycin HCL (FDA)
Etoposide( FDA)

Etoposide( FDA)
Diosmin(CEP FDA GMP)

Diosmin(CEP FDA GMP)
Gemfibrozil (FDA)

Gemfibrozil (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service